CA2239976A1 - Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate - Google Patents

Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate Download PDF

Info

Publication number
CA2239976A1
CA2239976A1 CA 2239976 CA2239976A CA2239976A1 CA 2239976 A1 CA2239976 A1 CA 2239976A1 CA 2239976 CA2239976 CA 2239976 CA 2239976 A CA2239976 A CA 2239976A CA 2239976 A1 CA2239976 A1 CA 2239976A1
Authority
CA
Canada
Prior art keywords
oligonucleotides
seq
oligonucleotide
gene
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2239976
Other languages
English (en)
French (fr)
Inventor
Paul A. Zamecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Worcester Foundation for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Foundation for Biomedical Research filed Critical Worcester Foundation for Biomedical Research
Publication of CA2239976A1 publication Critical patent/CA2239976A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2239976 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate Abandoned CA2239976A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US401895P 1995-09-20 1995-09-20
US60/004,018 1995-09-20

Publications (1)

Publication Number Publication Date
CA2239976A1 true CA2239976A1 (en) 1997-03-27

Family

ID=21708727

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2239976 Abandoned CA2239976A1 (en) 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate

Country Status (4)

Country Link
EP (1) EP0851919A1 (de)
AU (1) AU7366296A (de)
CA (1) CA2239976A1 (de)
WO (1) WO1997011170A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2487328A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd. Sirna for control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN1213057C (zh) * 1998-11-09 2005-08-03 中国人民解放军军事医学科学院放射医学研究所 抑制端粒酶活性反义寡核苷酸结构及用途
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
ES2728168T3 (es) 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
AR041407A1 (es) * 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US20100286229A1 (en) * 2005-09-30 2010-11-11 Katerina Gurova Modulation of Androgen Receptor for Treatment of Prostate Cancer
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009068033A2 (en) 2007-11-26 2009-06-04 Santaris Pharma A/S Lna antagonists targeting the androgen receptor
EP2646553A4 (de) 2010-11-12 2015-01-07 Santaris Pharma As Zusammensetzungen und verfahren zur behandlung androgenrezeptorabhängiger erkrankungen einschliesslich krebs
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
CN105143463A (zh) 2013-02-25 2015-12-09 诺华股份有限公司 新的雄激素受体突变
WO2015066442A1 (en) * 2013-11-01 2015-05-07 Everon Biosciences, Inc. Molecular targets for selective eradication of senescent cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
WO1994005268A1 (en) * 1992-09-04 1994-03-17 Baylor College Of Medicine Novel triplex forming oligonucleotides and methods for their use
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5556956A (en) * 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Also Published As

Publication number Publication date
AU7366296A (en) 1997-04-09
WO1997011170A1 (en) 1997-03-27
EP0851919A1 (de) 1998-07-08

Similar Documents

Publication Publication Date Title
US7420050B2 (en) TGF-β-specific covalently closed antisense molecule
CA2239976A1 (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US5783683A (en) Antisense oligonucleotides which reduce expression of the FGFRI gene
US5734039A (en) Antisense oligonucleotides targeting cooperating oncogenes
FI112379B (fi) Menetelmä terapeuttisesti käyttökelpoisten oligonukleotidien valmistamiseksi
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
SK3652003A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
TWI761305B (zh) 抑制Ｈｉｆ２α基因表現之組合物及方法
JPH09507381A (ja) 血管平滑筋細胞の増殖の阻害
EP2488210A2 (de) Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
WO1991018625A1 (en) Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
EP1144609B1 (de) Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
CA2105595A1 (en) Antisense polynucleotides
JPH10502820A (ja) 腫瘍増殖、浸潤および転移を阻害するためのオリゴヌクレオシド化合物および方法
EP0668782B1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
Rubenstein et al. Antisense oligonucleotide intralesional therapy for human PC‐3 prostate tumors carried in athymic nude mice
WO1995024223A1 (en) Inhibition of cell proliferation by e2f-1 antisense oligonucleotides
EP1071764B1 (de) Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit
CA2223109A1 (en) Use of antisense oligonucleotides to il-6 receptor mrna to inhibit cellular proliferation
CA2232390A1 (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
WO1998013072A1 (en) Compositions for and methods of treating multiple drug resistance
CA2446606A1 (en) Inhibitors of dna methyltransferase isoforms
WO1998049287A2 (en) Antisense oligonucleotides specific for thymidylate synthase
US20030176384A1 (en) Antisense oligonucleotides for the inhibition of integrin alphav -subunit expression
AU2003271376B8 (en) Antisense Oligonucleotides for the Inhibition of Integrin alpha-Subunit Expression

Legal Events

Date Code Title Description
FZDE Dead